Viewing Study NCT01320020


Ignite Creation Date: 2025-12-25 @ 4:29 AM
Ignite Modification Date: 2026-01-17 @ 4:16 AM
Study NCT ID: NCT01320020
Status: TERMINATED
Last Update Posted: 2013-07-02
First Post: 2011-03-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Sponsor: Neovii Biotech
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Epithelial Cancer Patients View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Cancer View
None Neoplasm View
None Carcinoma View
None intravenous View
None Monoclonal Antibody View
None Removab View